-
EP2605757
European procedure
Extract from the Register of European Patents
EP About this file: EP2605757
| EP2605757 - NALBUPHINE-BASED FORMULATIONS AND USES THEREOF [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 06.05.2016 Database last updated on 31.08.2024 | Most recent event Tooltip | 06.05.2016 | No opposition filed within time limit | published on 08.06.2016 [2016/23] | Applicant(s) | For all designated states Debregeas Et Associes Pharma 79 rue de Miromesnil 75008 Paris / FR | [2013/26] | Inventor(s) | 01 /
LEBON, Christophe 2 chemin de la Bénétrie F-28260 Rouvres / FR | 02 /
SUPLIE, Pascal 11 rue du 8 mai 1945 F-27400 Montaure / FR | 03 /
PAUL, David Olivier 7 ruelle Bernage F-28100 Dreux / FR | [2013/26] | Representative(s) | Gallochat, Alain 39, rue du Clos de Paris 95170 Deuil La Barre / FR | [2013/26] | Application number, filing date | 11758519.0 | 18.08.2011 | WO2011FR51929 | Priority number, date | FR20100056689 | 20.08.2010 Original published format: FR 1056689 | [2013/26] | Filing language | FR | Procedural language | FR | Publication | Type: | A2 Application without search report | No.: | WO2012022919 | Date: | 23.02.2012 | Language: | FR | [2012/08] | Type: | A2 Application without search report | No.: | EP2605757 | Date: | 26.06.2013 | Language: | FR | The application published by WIPO in one of the EPO official languages on 23.02.2012 takes the place of the publication of the European patent application. | [2013/26] | Type: | B1 Patent specification | No.: | EP2605757 | Date: | 01.07.2015 | Language: | FR | [2015/27] | Search report(s) | International search report - published on: | EP | 10.05.2012 | Classification | IPC: | A61K9/20, A61K9/28, A61K9/50, A61K31/485, A61K47/10, A61K47/36, A61K47/26, A61K47/02, A61P25/04 | [2013/26] | CPC: |
A61K31/485 (EP,KR,US);
A61K9/20 (KR);
A61K9/0053 (US);
A61K9/2009 (US);
A61K9/2013 (US);
A61K9/2018 (EP,US);
A61K9/2027 (US);
A61K9/28 (KR);
A61K9/2866 (EP,US);
A61K9/50 (KR);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/30 (EP);
A61P25/36 (EP);
A61P29/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/26] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | AUF NALBUPHIN BASIERENDE FORMULUERUNGEN UND IHRE VERWENDUNG | [2013/26] | English: | NALBUPHINE-BASED FORMULATIONS AND USES THEREOF | [2013/26] | French: | FORMULATIONS A BASE DE NALBUPHINE ET LEURS UTILISATIONS | [2013/26] | Entry into regional phase | 27.12.2012 | National basic fee paid | 27.12.2012 | Designation fee(s) paid | 27.12.2012 | Examination fee paid | Examination procedure | 14.01.2013 | Examination requested [2013/26] | 17.09.2013 | Amendment by applicant (claims and/or description) | 28.01.2014 | Despatch of a communication from the examining division (Time limit: M04) | 25.02.2014 | Reply to a communication from the examining division | 23.04.2014 | Despatch of a communication from the examining division (Time limit: M04) | 28.07.2014 | Reply to a communication from the examining division | 04.02.2015 | Despatch of a communication from the examining division (Time limit: M01) | 04.03.2015 | Reply to a communication from the examining division | 19.03.2015 | Communication of intention to grant the patent | 15.05.2015 | Receipt of the translation of the claim(s) | 18.05.2015 | Fee for grant paid | 18.05.2015 | Fee for publishing/printing paid | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.01.2014 | Opposition(s) | 04.04.2016 | No opposition filed within time limit [2016/23] | Fees paid | Renewal fee | 14.08.2013 | Renewal fee patent year 03 | 22.08.2014 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IY]US4366159 (MAGRUDER MICHAEL R) [I] 1,16,18 * column 2, lines 3-10 * * column 7, lines 14-23 * [Y] 2-15,17; | [Y]US4282215 (DUDZINSKI JOHN R, et al) [Y] 2-15,17 * column 1, lines 16-17 * * column 3, lines 45-56 *; | [A]US2009030026 (BAICHWAL ANAND R [US], et al) [A] 1-18 * the whole document * | [A] - LO, M. W. ET AL, "The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, (19870101), vol. 27, ISSN 0091-2700, pages 866 - 873, XP009143126 [A] 1-18 * the whole document * | [A] - AUNGST, B.J. ET AL, "Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs.", BIOPHARM DRUG DISPOS, (1985), vol. 6, pages 413 - 421, XP002616787 [A] 1-18 * the whole document * DOI: http://dx.doi.org/10.1002/bdd.2510060407 | Examination | WO03028703 | by applicant | WO8203768 | WO9800951 | WO0024386 | US6680067 | RU2254852 | WO2007025005 |